Back to Search
Start Over
The Mutation Matters: <scp>CSF</scp> Profiles of <scp>GCase</scp> , Sphingolipids, α‐Synuclein in <scp> PD GBA </scp>
- Source :
- Movement disorders 36(5), 1216-1228 (2021). doi:10.1002/mds.28472
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Background With pathway-specific trials in PD associated with variants in the glucocerebrosidase gene (PDGBA ) under way, we need markers that confirm the impact of genetic variants in patient-derived biofluids in order to allow patient stratification merely based on genetics and that might serve as biochemical read-out for target engagement. Objective To explore GBA-pathway-specific biomarker profiles cross-sectionally (TUEPAC-MIGAP, PPMI) and longitudinally (PPMI). Methods We measured enzyme activity of the lysosomal glucocerebrosidase, CSF levels of glucosylceramides (upstream substrate of glucocerebrosidase), CSF levels of ceramides (downstream product of glucocerebrosidase), lactosylceramides, sphingosines, sphingomyelin (by-products) and CSF levels of total α-synuclein in PDGBA patients compared to PDGBA_wildtype patients. Results Cross-sectionally in both cohorts and longitudinally in PPMI: (1) glucocerebrosidase activity was significantly lower in PDGBA compared to PDGBA_wildtype . (2) CSF levels of upstream substrates (glucosylceramides species) were higher in PDGBA compared to PDGBA_wildtype . (3) CSF levels of total α-synuclein were lower in PDGBA compared to PDGBA_wildtype . All of these findings were most pronounced in PDGBA with severe mutations (PDGBA_severe ). Cross-sectionally in TUEPAC-MIGAP and longitudinally in PPMI, CSF levels of downstream-products (ceramides) were higher in PDGBA_severe . Cross-sectionally in TUEPAC-MIGAP by-products sphinganine and sphingosine-1-phosphate and longitudinally in PPMI species of by-products lactosylceramides and sphingomyelin were higher in PDGBA_severe . Interpretation These findings confirm that GBA mutations have a relevant functional impact on biomarker profiles in patients. Bridging the gap between genetics and biochemical profiles now allows patient stratification for clinical trials merely based on mutation status. Importantly, all findings were most prominent in PDGBA with severe variants. © 2021 International Parkinson and Movement Disorder Society.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
genetics [Mutation]
CSF
Biology
medicine.disease_cause
genetics [Glucosylceramidase]
03 medical and health sciences
α-synuclein
0302 clinical medicine
genetics [Parkinson Disease]
Internal medicine
medicine
Humans
GCase
ddc:610
Sphingolipids
Mutation
ceramides
Wild type
Parkinson Disease
Sphingolipid
030104 developmental biology
Endocrinology
Neurology
genetics [alpha-Synuclein]
alpha-Synuclein
Glucosylceramidase
Biomarker (medicine)
GBA
Neurology (clinical)
Lactosylceramides
Sphingomyelin
Glucocerebrosidase
Glucosylceramides
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 15318257 and 08853185
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Movement Disorders
- Accession number :
- edsair.doi.dedup.....745d5d85c91896a1fbffc64c3f3a16c6